Why the study?
Little is known about the factors involved in clot stability in cancer patients with VTE, and angiogenesis may possibly be implicated.
Does antiangiogenic therapy increase the proportion of pulmonary embolism in cancer patients with venous thromboembolism?
Does antiangiogenic therapy increase the proportion of pulmonary embolism in cancer patients with venous thromboembolism?
Antiangiogenic therapies are associated with a significantly higher proportion of pulmonary embolism among cancer patients presenting with venous thromboembolism, suggesting a potential effect on clot stability.
Answers are grounded in this paper and cite their sources.
Antiangiogenic exposure was associated with higher PE proportion in cancer VTE; leaves open effect on clot stability, requiring prospective confirmation.
Background Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis possibly being implicated. Methods The database is from the TESEO prospective registry that recruits cancer patients with VTE from 41 Spanish hospitals. Independent validation was conducted in a cohort from the Caravaggio trial. The objective is to evaluate the association between exposure to antiangiogenic therapies and the PE/VTE proportion in oncological patients. Results In total, 1,536 subjects were evaluated; 58.4% (n = 894) had a PE and 7% (n = 108) received antiangiogenic therapy (bevacizumab in 75%). The PE/VTE proportion among antiangiogenic-treated individuals was 77/108 (71.3%) versus 817/1,428 (57.2%) among those receiving other alternative therapies (p = 0.004). The effect of the antiangiogenics on the PE/VTE proportion held up across all subgroups except for active smokers or those with chronic obstructive pulmonary disease. Exposure to antiangiogenics was associated with increased PEs, odds ratio (OR) 2.27 (95% CI, 1.42–3.63). In the Caravaggio trial, PE was present in 67% of the individuals treated with antiangiogenics, 50% of those who received chemotherapy without antiangiogenic treatment, and 60% without active therapy (p = 0.0016). Conclusion Antiangiogenics are associated with increased proportion of PE in oncological patients with VTE. If an effect on clot stability is confirmed, the concept of thrombotic risk in cancer patients should be reconsidered in qualitative terms.
No takes yet. Share an insight, caveat, or question.
Carmona‐Bayonas et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: